Previous 10 | Next 10 |
The following slide deck was published by Aerie Pharmaceuticals, Inc. in conjunction with this event. For further details see: Aerie Pharmaceuticals (AERI) Axitinib Implant (AR-14034) Overview - Slideshow
Aerie Pharmaceuticals shares rise ([[AERI]] +7.0%) after the company posted fourth-quarter revenue that beat Wall Street estimates, helped by higher shipments for its Rhopressa and Rocklatan treatments in the quarter. The company, however, stayed away from providing financial ...
Aerie Pharmaceuticals, Inc. (AERI) Q4 2020 Earnings Conference Call February 25, 2021 17:00 Company Participants Ami Bavishi - Director of Investor Relations Vince Anido - Chairman & Chief Executive Officer Tom Mitro - President & Chief Operating Officer Rich Rubino - Chief Financial ...
2020 Net Revenues of $83.1 Million Increased 19% over 2019 Fourth Quarter Net Revenues of $24.7 Million or $80 Per Bottle New Sustained Release Pan-VEGF Inhibitor Pipeline Candidate Announced Today Conference Call and Webcast Today, February 25 th , at 5:00...
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, announced today ...
The European Commission ((EC)) has granted marketing authorisation for Aerie Pharmaceuticals's (AERI) of Roclanda (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.The produc...
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced ...
The European Medicines Agency's advisory group CHMP has adopted a positive opinion backing approval of Aerie Pharmaceuticals' (AERI) Roclanda (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% for the reduction of elevated intraocular pressure ((IOP)) in adult patients with primary...
-European Commission Decision Anticipated in Approximately Two Months- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open...
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced ...
News, Short Squeeze, Breakout and More Instantly...
Aerie Pharmaceuticals Inc. Company Name:
AERI Stock Symbol:
NASDAQ Market:
Aerie Pharmaceuticals Inc. Website:
Leveraging Alcon’s robust commercial capabilities and resources to drive further growth and access to Rocklatan and Rhopressa Acquisition adds pharmaceutical research and development capabilities and further expertise for future product pipeline Expands Al...
Third Quarter Glaucoma Franchise Net Revenues of $36.1 Million, up 23% over Third Quarter 2021 Previously Announced Agreement to be Acquired by Alcon; Transaction Expected to Close in the Fourth Quarter of 2022 Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceut...
NEW YORK, NY / ACCESSWIRE / October 30, 2022 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Altra Industrial Motion Corp. (NA...